论文部分内容阅读
目的探讨蜂胶类黄酮对肺结核合并糖尿病(PTB-DM)患者的辅助治疗作用及其免疫调节机制,为寻求安全有效的PTB-DM防治措施提供参考。方法以PTB-DM患者120人为对象,利用随机数字表随机分为A、B、C三组,每组40人,A、B组分别按1 000、2 000 mg/d剂量口服含蜂胶类黄酮的蜂胶软胶囊,C组口服不含蜂胶类黄酮的蜂胶基质软胶囊作为对照,观察6个月,比较各组疗效差异、试验前后WBC及分类、T淋巴细胞亚群CD3~+、CD4~+、CD8~+、CD4~+/CD8~+比值的差异。结果三组有效率差异有统计学意义(P=0.005),其中B组为94.6%、A组为76.9%、C组为64.1%;细胞免疫7项指标差异有统计学意义(P=0.000),其中WBC计数、中性粒细胞百分比为B组高于A与C组,淋巴细胞百分比为B组最高、A组其次、C组最低;T淋巴细胞:CD3~+、CD4~+为B组>A组>C组,CD8~+的组间差异无统计学意义(P>0.05),CD4~+/CD8~+比值为A与B组高于C组。结论蜂胶类黄酮对PTB-DM患者具有辅助治疗作用,可改善WBC及分类、T淋巴细胞亚群CD3~+、CD4~+、CD4~+/CD8~+比值等指标,增强细胞免疫水平具有作用,且有剂量差异。
Objective To investigate the adjuvant therapeutic effect of propolis flavonoids on patients with pulmonary tuberculosis complicated with diabetes mellitus (PTB-DM) and its immunoregulatory mechanism, so as to provide a reference for seeking safe and effective PTB-DM prevention and treatment. Methods A total of 120 patients with PTB-DM were randomly divided into three groups (A, B and C), 40 patients in each group. Groups A and B were treated with propolis flavonoids Propolis soft capsules of group C were given orally. Propolis soft capsules without oral administration of propolis flavonoids were used as a control. The difference of efficacy between the groups was observed after 6 months. Before and after the test, WBC and classification, T lymphocyte subsets CD3 +, CD4 + , CD8 ~ +, CD4 ~ + / CD8 ~ + ratio of the difference. Results The effective rates of the three groups were statistically significant (P = 0.005), of which 94.6% in group B, 76.9% in group A and 64.1% in group C, and there were significant differences among the 7 indicators in cellular immunity (P = 0.000) , The percentage of neutrophils was higher in group B than in groups A and C, the percentage of lymphocytes was the highest in group B, the lowest in group A, and the lowest in group C; The percentage of T lymphocytes: CD3 ~ + and CD4 ~ + was in group B (P> 0.05). The ratio of CD4 ~ + / CD8 ~ + in group A> C and CD8 ~ + was higher in group A and group B than group C. Conclusion Propolis flavonoids have the adjuvant therapeutic effect on patients with PTB-DM, which can improve the indexes of WBC and classification, T lymphocyte subsets CD3 ~ +, CD4 ~ +, CD4 ~ + / CD8 ~ + and enhance the cellular immunity level , And there is a dose difference.